1-7 of 7
Stephen D. Gillies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Frederick Lansigan, MD, Ryotaro Nakamura, MD, Donald P. Quick, MD, Daniel Vlock, MD, Andrew Raubitschek, MD, Stephen D. Gillies, PhD, Veronika Bachanova, MD
Journal: Blood
Blood (2016) 128 (22): 620.
https://doi.org/10.1182/blood.V128.22.620.620
Published: 2016
Journal Articles

An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma

Stephen D. Gillies, Yan Lan, Steven Williams, Frank Carr, Stephen Forman, Andrew Raubitschek, Kin-Ming Lo
Journal: Blood
Blood (2005) 105 (10): 3972–3978.
https://doi.org/10.1182/blood-2004-09-3533
Published: 2005
Journal Articles

Human Lymphoid and Myeloid Cell Development in NOD/LtSz- scid IL2r γ null Mice Engrafted with Mobilized Human Hematopoietic Stem Cells.

Leonard Shultz, Ph.D., Bonnie L. Lyons, D.V.M., Lisa M. Burzenski, B.S., Bruce Gott, X. Chen, Ph.D., Stanley Chaleff, M.D., Malak Kotb, Ph.D., Stephen D. Gillies, Ph.D., Dale L. Greiner, Ph.D., Rupert Handgretinger, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 248.
https://doi.org/10.1182/blood.V104.11.248.248
Published: 2004
Journal Articles

The Novel De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 Is Effective in SCID Mice Bearing Rituximab-Resistant Human Lymphoma Xenografts.

Jan O. Staak, MD, David Colcher, PhD, Scott Lauder, Jianyi Wang, Stephen D. Gillies, MD, Andrew A. Raubitschek, MD
Journal: Blood
Blood (2004) 104 (11): 3288.
https://doi.org/10.1182/blood.V104.11.3288.3288
Published: 2004
Journal Articles

Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma

Ursula Pertl, Harald Wodrich, J. Michael Ruehlmann, Stephen D. Gillies, Holger N. Lode, Ralph A. Reisfeld
Journal: Blood
Blood (2003) 101 (2): 649–654.
https://doi.org/10.1182/blood-2002-02-0391
Published: 2003
Journal Articles

Antidisialoganglioside/granulocyte macrophage–colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis

Leonid S. Metelitsa, Stephen D. Gillies, Michael Super, Hiroyuki Shimada, C. Patrick Reynolds, Robert C. Seeger
Journal: Blood
Blood (2002) 99 (11): 4166–4173.
https://doi.org/10.1182/blood.V99.11.4166
Published: 2002
Journal Articles

Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

Holger N. Lode, Rong Xiang, Torsten Dreier, Nissi M. Varki, Stephen D. Gillies, Ralph A. Reisfeld
Journal: Blood
Blood (1998) 91 (5): 1706–1715.
https://doi.org/10.1182/blood.V91.5.1706
Published: 1998